The Effectiveness of No or Low-Dose Versus High-Dose Aspirin in Treating Acute Kawasaki Disease: A Systematic Review and Meta-Analysis

Overview

Journal Clin Pract

Publisher MDPI

Specialty General Medicine

Date 2024 Jul 25

PMID 39051299

Authors

Fatemah M Safar

Waleed M Kaabi

Reem S Aljudaibi

Lama M Alsaidi

Sarah S Alharbi

Areen Y Ibrahim

Haneen A Alghamdi

Noura O Alshami

Nora M AlZoum

Amani Y Alfaya

Fatema R Alrashed

Affiliations

Soon will be listed here.

Abstract

This systematic review and meta-analysis assesses the effectiveness of no or low-dose versus high-dose aspirin on the incidence of coronary artery aneurysms (CAAs), intravenous immunoglobulin (IVIG) resistance, hospital stay length, and fever duration during the acute phase of Kawasaki disease. Our review adheres to the Preferred Reporting Items for Systematic Reviews guidelines. The PubMed and Google Scholar databases were comprehensively searched to identify relevant studies in the literature, including observational studies and randomized controlled trials (RCTs). The primary outcome was the incidence of CAAs. The secondary outcomes were the hospital stay length, fever duration, and IVIG resistance. The risk of bias was assessed using the Newcastle-Ottawa scale for cohort studies and Cochrane's Risk of Bias Tool for RCTs. The data were analyzed using the Review Manager software. Twelve studies with a total of 68,495 participants met the inclusion criteria. The incidences of CAAs (odds ratio [OR] = 0.93; 95% confidence interval [CI] = 0.64-1.34) and IVIG resistance (OR = 1.46; 95% CI = 1.00-2.12) did not differ significantly between no or low-dose versus high-dose aspirin in treating acute KD. Moreover, the fever durations (mean difference [MD] = 3.55 h; 95% CI = -7.99-15.10) and hospital stay lengths (MD = -0.54 days; 95% CI = -2.50-1.41) were similar in the no and low-dose aspirin group compared to the high-dose aspirin group. Our review indicates that there are no significant differences in the incidences of CAA and IVIG resistance, fever durations, and hospital stay lengths between no or low-dose versus high-dose aspirin in treating the acute phase of KD.

References

Suzuki T, Michihata N, Hashimoto Y, Yoshikawa T, Saito K, Matsui H . Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan. Eur J Pediatr. 2023; 183(1):415-424. DOI: 10.1007/s00431-023-05302-8. View

Dallaire F, Dahdah N . New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr. 2010; 24(1):60-74. DOI: 10.1016/j.echo.2010.10.004. View

Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y . JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. Circ J. 2020; 84(8):1348-1407. DOI: 10.1253/circj.CJ-19-1094. View

Dallaire F, Fortier-Morissette Z, Blais S, Dhanrajani A, Basodan D, Renaud C . Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics. 2017; 139(6). DOI: 10.1542/peds.2017-0098. View

Chiang M, Liu H, Wang J . Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. Arch Dis Child. 2020; 106(7):662-668. DOI: 10.1136/archdischild-2019-318245. View

Lee G, Lee S, Hong Y, Sohn S . Is high-dose aspirin necessary in the acute phase of kawasaki disease?. Korean Circ J. 2013; 43(3):182-6. PMC: 3629244. DOI: 10.4070/kcj.2013.43.3.182. View

McCrindle B, Rowley A, Newburger J, Burns J, Bolger A, Gewitz M . Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017; 135(17):e927-e999. DOI: 10.1161/CIR.0000000000000484. View

Jia X, Du X, Bie S, Li X, Bao Y, Jiang M . What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis. Rheumatology (Oxford). 2020; 59(8):1826-1833. DOI: 10.1093/rheumatology/keaa050. View

Nagata S . Causes of Kawasaki Disease-From Past to Present. Front Pediatr. 2019; 7:18. PMC: 6371652. DOI: 10.3389/fped.2019.00018. View

10.

Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B . Effect of different doses of aspirin on the prognosis of Kawasaki disease. Pediatr Rheumatol Online J. 2020; 18(1):48. PMC: 7291457. DOI: 10.1186/s12969-020-00432-x. View

11.

Kim G, Yu J, Yoon K, Jeong S, Song Y, Han J . Medium- or Higher-Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes. J Pediatr. 2017; 184:125-129.e1. DOI: 10.1016/j.jpeds.2016.12.019. View

12.

Kwon J, Roh D, Kim Y . The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid. Children (Basel). 2020; 7(10). PMC: 7602855. DOI: 10.3390/children7100185. View

13.

Zheng X, Yue P, Liu L, Tang C, Ma F, Zhang Y . Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis. PLoS One. 2019; 14(5):e0217274. PMC: 6531010. DOI: 10.1371/journal.pone.0217274. View

14.

Saulsbury F . Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr (Phila). 2002; 41(8):597-601. DOI: 10.1177/000992280204100807. View

15.

Durongpisitkul K, Gururaj V, Park J, Martin C . The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995; 96(6):1057-61. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

17.

Kuo H, Lo M, Hsieh K, Guo M, Huang Y . High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. PLoS One. 2015; 10(12):e0144603. PMC: 4686074. DOI: 10.1371/journal.pone.0144603. View

18.

Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J . Aspirin Dose in Kawasaki Disease: The Ongoing Battle. Arthritis Care Res (Hoboken). 2017; 70(10):1536-1540. DOI: 10.1002/acr.23504. View

19.

Sanati F, Bagheri M, Eslami S, Khalooei A . Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm. Ann Pediatr Cardiol. 2021; 14(2):146-151. PMC: 8174624. DOI: 10.4103/apc.APC_206_20. View

20.

Manlhiot C, Millar K, Golding F, McCrindle B . Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol. 2009; 31(2):242-9. DOI: 10.1007/s00246-009-9599-7. View